|
Search for our Investigators on Pub
Med
|
CHRISTINA VOELKEL-JOHNSON, Ph.D.
Lab
LAB PERSONNEL
Christina Voelkel-Johnson, Ph.D. Assistant Professor, MUSC
PUBLICATIONS
Voelkel-Johnson C, Hannun YA, El-Zawahry A. Resistance to
TRAIL is associated with defects in ceramide signaling that
can be overcome by exogenous C6-ceramide without requiring
down-regulation of cellular FLICE inhibitory protein. Mol
Cancer Ther. 2005 Sep;4(9):1320-7.
El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C. In vitro
efficacy of AdTRAIL gene therapy of bladder cancer is
enhanced by trichostatin A-mediated restoration of CAR
expression and downregulation of cFLIP and Bcl-X(L). Cancer
Gene Ther. 2005 Sep 16
El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin
increases the effectiveness of Apo2L/TRAIL for tumor growth
inhibition of prostate cancer xenografts. BMC Cancer. 2005
Jan 7;5(1):2.
Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY,
Norris JS. In vitro efficacy of Fas ligand gene therapy for
the treatment of bladder cancer. Cancer Gene Ther. 2005
Jan;12(1):12-8.
Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C,
Norris JS, Dong JY. Enhanced apoptosis of glioma cell lines
is achieved by co-delivering FasL-GFP and TRAIL with a
complex Ad5 vector. Cancer Gene Ther. 2003
Nov;10(11):814-22.
Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in
combination with doxorubicin selectively kills malignant but
not normal prostate cells. Cancer Biol Ther. 2003
May-Jun;2(3):283-90.
Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin
pretreatment sensitizes prostate cancer cell lines to TRAIL
induced apoptosis which correlates with the loss of c-FLIP
expression. Cancer Biol Ther. 2002 Sep-Oct;1(5):520-7.
Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S,
Dong JY. The use of Fas Ligand, TRAIL and Bax in gene
therapy of prostate cancer. Curr Gene Ther. 2001
May;1(1):123-36.
Voelkel-Johnson C, King DL, Norris JS. Resistance of
prostate cancer cells to soluble TNF-related
apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by
doxorubicin or adenoviral delivery of full-length TRAIL.
Cancer Gene Ther. 2002 Feb;9(2):164-72.
Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS.
Intracellular Fas ligand expression causes Fas-mediated
apoptosis in human prostate cancer cells resistant to
monoclonal antibody-induced apoptosis. Mol Ther. 2000
Oct;2(4):348-58.
Voelkel-Johnson C, Voeks DJ, Greenberg NM, Barrios R,
Maggouta F, Kurtz DT, Schwartz DA, Keller GM, Papenbrock T,
Clawson GA, Norris JS. Genomic instability-based transgenic
models of prostate cancer. Carcinogenesis. 2000
Aug;21(8):1623-7.
O'Brien JB, Piddington DL, Voelkel-Johnson C, Richards DJ,
Hadley LA, Laster SM. Sustained phosphorylation of cytosolic
phospholipase A2 accompanies cycloheximide- and
adenovirus-induced susceptibility to TNF. J Immunol. 1998
Aug 1;161(3):1525-32.
Thorne TE, Voelkel-Johnson C, Casey WM, Parks LW, Laster SM.
The activity of cytosolic phospholipase A2 is required for
the lysis of adenovirus-infected cells by tumor necrosis
factor. J Virol. 1996 Dec;70(12):8502-7.
Voelkel-Johnson C, Thorne TE, Laster SM. Susceptibility to
TNF in the presence of inhibitors of transcription or
translation is dependent on the activity of cytosolic
phospholipase A2 in human melanoma tumor cells. J Immunol.
1996 Jan 1;156(1):201-7.
Voelkel-Johnson C, Entingh AJ, Wold WS, Gooding LR, Laster
SM. Activation of intracellular proteases is an early event
in TNF-induced apoptosis. J Immunol. 1995 Feb
15;154(4):1707-16.
Zilli D, Voelkel-Johnson C, Skinner T, Laster SM. The
adenovirus E3 region 14.7 kDa protein, heat and sodium
arsenite inhibit the TNF-induced release of arachidonic
acid. Biochem Biophys Res Commun. 1992 Oct 15;188(1):177-83.
For recent
abstracts, click here
|
